Le Lézard
Classified in: Science and technology
Subject: PER

Riley McNulty to Address AI's Role in Customer Experience at Document Strategy Forum 2024


Riley McNulty of Keypoint Intelligence will present at the Document Strategy Forum 2024 in Boston on May 20. His talk will explore the evolution of customer experience influenced by AI, focusing on its impact on communications software and the document and printing industries.

FAIRFIELD, N.J., April 30, 2024 /PRNewswire-PRWeb/ -- Keypoint Intelligence is pleased to announce that Riley McNulty, Vice President of Customer Experience & Consulting at Keypoint Intelligence, will speak at the Document Strategy Forum 2024 from May 20-22 in Boston. He will be presenting "Shaping Tomorrow's Journeys: The Evolution of Customer Experience in an AI-Inspired World" on May 20, from 10:00 AM to 10:50 AM. This session will provide a comprehensive outlook on the intersection of customer communications software, customer experience, and the document and printing industries.

Attendees will be equipped with actionable insights into several key objectives crucial for businesses that leverage AI to enhance customer experience. These include:

Riley has been working in the document output industry for over 25 years. This deep-rooted experience in market research, strategic planning, and consulting, equips him with a unique perspective on the evolving market dynamics in the customer communications industry. Riley's approach, which combines quantitative analysis and qualitative insights, provides invaluable insights for those looking to innovate and improve their customer communication strategies. And, as an early adopter of AI, he will share how AI impacts the industry and how companies can use AI to drive better customer connections.

Join Riley to explore how AI is reshaping consumer engagement and the strategic moves that can place your business at the forefront of innovation. For more information, visit DSF '24 website.

About Keypoint Intelligence:
For 60 years, clients in the digital imaging industry have relied on Keypoint Intelligence for independent hands-on testing, lab data, and extensive market research to drive their product and sales success. Keypoint Intelligence has been recognized as the industry's most trusted resource for unbiased information, analysis, and awards due to decades of analyst experience.

For media inquiries, email: [email protected]. 

SOURCE Keypoint Intelligence


These press releases may also interest you

at 08:05
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
Takeda (TSE:4502/NYSE:TAK) and Pfizer today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® (brentuximab vedotin) in combination with chemotherapy as a late-breaking...

at 08:05
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
Summit Therapeutics Inc. ("Summit," "we," or the "Company") announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, "Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A...

at 08:05
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, announced data from an ongoing Phase 1 study of AC699 monotherapy in patients with ER-positive / HER2-negative locally advanced or...

at 08:05
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
Gilead Sciences, Inc. and Arcus Biosciences, Inc. today announced longer-term efficacy and safety results from Arm A1 of the Phase 2 EDGE-Gastric study. These updated data show consistent objective response rate (ORR) and provide mature...

at 08:05
Pfizer's ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/?Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Pfizer Inc. today announced detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse...

at 08:05
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
Bristol Myers Squibb today announced results from the Phase 3 KRYSTAL-12 study evaluating KRAZATI® (adagrasib) compared to standard of care chemotherapy in patients with locally advanced or metastatic KRASG12C-mutated non-small cell lung cancer...

More news about Science and technology...


News published on and distributed by: